Communiqués Camurus AB

Actions

CAMX

SE0007692850

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
615,00 ^SEK	+0,90%		0,00%	-0,16%

24/08	Pareto Securities procède à un reclassement interne de 0,6 % du capital de Camurus	FW
14/08	D. E. Shaw, nouveau vendeur à découvert déclaré chez Camurus	FW

Communiqués

17/07	Camurus : rsquo; NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA	PU
17/07	Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA	AQ
15/07	Camurus : rsquo; Interim Report Second Quarter 2026	PU
15/07	Camurus' Interim Report Second Quarter 2026	AQ
30/06	Change in number of shares and votes in Camurus	AQ
10/06	Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly	AQ
01/06	Camurus announces expansion of Lilly collaboration	AQ
01/06	Camurus : AGM Minutes 2026 (agm minutes 2026)	PU
29/05	Camurus : CEO Presentation (ceo presentation)	PU
28/05	Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2026/2029	AQ
28/05	Resolutions at the annual general meeting 2026 in Camurus	AQ
21/05	Camurus to present at Jefferies Global Healthcare Conference	AQ
13/05	Camurus (Q1 review): Revenues Below Expectations, but Robust Patient Growth	AQ
12/05	Camurus : rsquo; Interim Report January-March 2026 - Report	PU
12/05	Camurus' Interim Report January-March 2026	AQ
29/04	Camurus : Proposal by the Board of Directors on the implementation of a Performance Share Plan 2026/2029	PU
29/04	Camurus : Proposal by the Board of Directors on authorization for the Board of Directors to resolve on acquisition and transfer of own shares	PU
29/04	Camurus : Proposal by the BoD on authorization for the Board of Directors to resolve on issues of new shares and convertibles	PU
29/04	Camurus Annual Report for 2025	AQ
24/04	Camurus : Notice of annual general meeting 2026	PU
24/04	Camurus : Nomination Committees proposal to the annual general meeting 2026	PU
24/04	Notice of annual general meeting 2026 in Camurus AB (publ)	AQ
27/02	Change in number of shares and votes in Camurus	AQ
18/02	Camurus (Q4 review): Temporary UK Setback	AQ
17/02	Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer	AQ